Dissemin is shutting down on January 1st, 2025

Published in

Wiley, Health Services Research, 4(53), p. 2118-2132

DOI: 10.1111/1475-6773.12745

Links

Tools

Export citation

Search in Google Scholar

Medicare Spending for Breast, Prostate, Lung, and Colorectal Cancer Patients in the Year of Diagnosis and Year of Death

This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

ObjectiveTo characterize spending patterns for Medicare patients with incident breast, prostate, lung, and colorectal cancer.Data Sources/Study Setting/Study Design2007–2012 data from the Surveillance, Epidemiology, and End Results Program linked with Medicare fee‐for‐service claims.Data Collection/Extraction MethodsWe calculate per‐patient monthly and yearly mean and median expenditures, by cancer type, stage at diagnosis, and spending category, over the years of diagnosis and death.Principal FindingsOver the year of diagnosis, mean spending was $35,849, $26,295, $55,597, and $63,063 for breast, prostate, lung, and colorectal cancer, respectively. Over the year of death, spending was similar across different cancer types and stage at diagnosis.ConclusionsCharacterization of Medicare spending according to clinically meaningful categories may assist development of oncology alternative payment models and cost‐effectiveness models.